Page 4 - Nicolas Poirier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OSE Immuno: collaboration agreement with GenDx -November 21, 2023 at 12:13 pm EST

OSE Immunotherapeutics announces a collaboration agreement with GenDx to develop and validate a companion diagnostic test in preparation for the confirmatory pivotal Phase 3 clinical trial of.

United statesNicolas poirierGendx eurobio scientific groupEurobio scientific groupNext generation sequencingChief executive officerVitro diagnostic

OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi

OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRheinland pfalzFlorence portejoieNicolas poirierBoehringer ingelheimNantes university hospitalVeloxis pharmaceuticals incGendxa eurobio scientific companyEurobio scientific companyNon small cell lung cancerMaster collaboration agreementNext generation sequencingChief executive officerGeneral managerVitro diagnosticHuman leukocyte antigen

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPa Monoclonal Antibody

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPa Monoclonal Antibody
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Biberach an der rissBaden wübergUnited statesUniversity hospitalGunther kretschmarIhre chancenFlorence portejoieNoboru yamamotoJavier ferradaMartine gutierrezToshihiko doiManishr patelNicolas poirierRahima jamalStephan wojciekowskiIndiens wirtschaft

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

NANTES, France, October 16, 2023 Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

United statesNicolas poirierSilvia comisInternational conference on molecularHead of clinical developmentVeloxis pharmaceuticals incBoehringer ingelheimRegulatory affairsNantes university hospitalRegulatory newsMolecular targetsCancer therapeuticsClinical developmentDisease control rateMaximum tolerated doseNon small cell lung cancer

OSE Immunotherapeutics SA: OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

OSE Immunotherapeutics SA: OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFlorence portejoieNicolas poirierVeloxis pharmaceuticals incBoehringer ingelheimInternational conference on molecularRegulatory affairsNantes university hospitalSilvia comishead of clinical developmentRegulatory newsMolecular targetsCancer therapeuticsClinical developmentDisease control rateMaximum tolerated doseNon small cell lung cancer